Zoetis has been granted conditional release of their Canine Atopic Dermatitis Immunotherapeutic monoclonal antibody against IL-31. This injection has been developed for managing pruritus in dogs by binding their IL-31 with a monoclonal antibody.
Like Apoquel (oclacitinib), it has the potential to reduce pruritus within 24 to 48 hours with a single subcutaneous injection lasting up to 3 to 6 weeks depending on the dose and responsiveness of the patient.
Approximately 90% of patients respond well without suffering from the immunosuppressive effects of Apoquel. The injection appears to be less effective with non-allergy induced dermatitis and pruritus such as a bacterial pyoderma or Malassezia dermatitis.
This injectable is currently available to board-certified dermatologists and a small subset of practitioners throughout the country. The USDA has granted conditional release while collecting additional data. This new injectable is expected to be available to all referral partners by the end of 2016.
